RSV in Older Adults: Risks, Symptoms & Prevention

Respiratory syncytial virus (RSV) is increasingly recognized as a major cause of severe respiratory illness in older adults. While often dismissed as a "childhood virus," RSV causes an estimated 60,000–160,000 hospitalizations and 6,000–10,000 deaths annually in U.S. adults ≥65 years—comparable to seasonal influenza in some years.

Why Older Adults Are Vulnerable

• Immunosenescence: Age-related decline in T-cell function, antibody response, and innate immunity impairs viral clearance.
• Comorbidities: Chronic heart failure, COPD, asthma, coronary artery disease, diabetes, CKD reduce physiologic reserve.
• Frailty & functional impairment: Limits ability to clear secretions, mobilize, maintain nutrition.
• Exposure to young children: Grandparents, caregivers, and household contacts of young children (asymptomatic or mild shedders) face frequent exposure.
• Long-term care settings: Congregate living facilitates outbreaks.

Symptoms in Older Adults

Often mimic other respiratory illnesses—high index of suspicion needed:

• Upper respiratory: Runny nose, sore throat, cough, low-grade fever
• Lower respiratory: Worsening cough, dyspnea, wheezing, hypoxemia
• Systemic: Fatigue, anorexia, malaise, confusion (especially in frail/demented)
• Exacerbation of underlying disease: COPD/asthma flare, heart failure decompensation

Diagnosis

Multiplex PCR (nasopharyngeal swab) detecting RSV, influenza, SARS-CoV-2 simultaneously is standard. Rapid antigen tests exist but lower sensitivity in adults (lower viral loads).

Treatment

No specific antiviral for RSV in adults (ribavirin used rarely in severe immunocompromised). Management is supportive:

• Oxygen for hypoxemia
• Bronchodilators for wheezing/bronchospasm
• IV fluids, antipyretics
• Non-invasive or invasive ventilation for respiratory failure
• Treat co-infections (bacterial pneumonia)
• Monitor for cardiac complications (MI, arrhythmia, HF exacerbation)

Prevention

• Vaccination (New 2023+): Arexvy® (GSK, RSVPreF3) or Abrysvo® (Pfizer, RSVpreF)—single dose, ≥60 years. High efficacy vs. LRTI. Discuss with provider (shared clinical decision-making).
• Influenza & COVID-19 vaccination—co-circulation amplifies risk.
• Hand hygiene, masking in healthcare/crowded settings during RSV season.
• Avoid contact with sick children/adults.
• Optimize chronic disease management (COPD, HF, diabetes).

When to Seek Care

Prompt evaluation for: difficulty breathing, wheezing, chest pain, confusion, high fever, inability to maintain hydration, worsening chronic symptoms. Early intervention prevents complications.

RSV in older adults is underdiagnosed and undertreated. New vaccines are a landmark advance—ask your doctor if RSV vaccination is right for you.